These normalizing effects on insulin sensitivity and insulin resistance benefit people with metabolic syndrome and diabetes [reviewed in (74)] and likely extend to people with MS, as insulin resistance is associated with elevated disability scores (16, 17). Here, INS is linked to myeloid sarcoma.